From Summit to Synergy: Fangzhou Jianke and Wangshan Wangshui Deepen Strategic Collaboration in 'AI + Chronic Disease Management' to Co-Build a Digital-Intelligent Healthcare Future

On November 25, Fangzhou Pharmaceutical (HKEX: 06086) successfully held its Double 12 Core Partner Summit (hereinafter referred to as the “Partner Summit”) in Guangzhou. Themed “Uniting for Mutual Success, Intelligently Leading the Future,” the summit gathered core stakeholders in the internet healthcare industry—including experts, scholars, partners, and frontline practitioners—to jointly explore pathways for enhancing quality and efficiency in chronic disease management amid the wave of artificial intelligence.

At the Partner Summit, a significant milestone was reached with the signing of a strategic cooperation agreement between Fangzhou Pharmaceutical and Suzhou Vigonvita Life Sciences Co., Ltd. (hereinafter referred to as “Vigonvita”). This partnership exemplifies the precise alignment and efficient complementarity of core industrial resources with digital intelligence capabilities. Moving forward, both parties will focus on product pipeline collaboration and digital-intelligent marketing as entry points, jointly exploring innovative strategies empowered by AI to inject strong momentum into the high-quality development of the greater health industry.

On October 24, the Ministry of Science and Technology explicitly proposed the comprehensive implementation of the “AI+” initiative to empower industries across the board at a press conference on the spirit of the Fourth Plenary Session of the 20th Central Committee of the Communist Party of China. On November 4, the National Health Commission issued the Implementation Opinions on Promoting and Regulating the Development of “AI + Healthcare” Applications, clearly outlining the core development goals and implementation pathways for medical AI over the next five years.

National-level policy support has charted the key development direction for the industry. At the Partner Summit, Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, drew upon the overarching trends shaping the sector to provide an in-depth analysis of the industrial opportunities arising from policy guidance and technological transformation.“AI + healthcare is the most significant area to watch in the coming years. Particularly in China, where population aging and the trend of chronic diseases affecting younger individuals are intensifying, AI technology is poised to play a pivotal role,” emphasized Xie Fangmin. As a company with years of deep expertise in chronic disease management, Fangzhou Pharmaceutical has remained steadfast in its core philosophy of “solving real problems and driving genuine change” in its exploration and development of application scenarios for “AI + chronic disease management.”

Address by Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical

Taking the “AI Health Manager” launched by Fangzhou Pharmaceutical’s platforms as an example, when users access and utilize the “Report Interpretation” feature through designated entry points, their trust accumulates continuously through multi-turn questioning and iterative communication, thereby enhancing loyalty and further driving the conversion of commercial value.A set of data illustrates the changes brought about by the application of AI technology: in October this year, the number of users experiencing AI features on Fangzhou Pharmaceutical’s platform was 2.4 times that of September month-on-month, while the Gross Merchandise Volume (GMV) saw a robust increase of 50%.

In Xie Fangmin’s view, strengthening the AI technological foundation should not only drive “quality growth” in business but also address the pain points of traditional management models—where “hospitals struggle to provide effective management and families are unable to manage care”—by identifying key breakthroughs that enable more people to access more professional and efficient health services. Xie Fangmin stated, “Achieving this goal cannot rely solely on individual corporate efforts. I look forward to collaborating with industry partners to develop a series of replicable and scalable ‘AI + Chronic Disease Management’ digital-intelligence solutions, thereby propelling the broader health industry into a new stage of high-quality development.”

As the wave of artificial intelligence sweeps across the globe and digital technologies reshape industrial landscapes, the healthcare industry is entering a new era characterized by ecological collaboration and deep integration. Disruptive technological innovations are not only restructuring the industry landscape but also giving rise to convergent paradigms such as “technology + industry” and “product + service.”

At the Partner Summit, Fangzhou Pharmaceutical officially announced a strategic partnership with Vigonvita. This collaboration is not merely a simple aggregation of resources, but a strategic alignment based on industry development trends and core user needs. It aims to break down industrial barriers by deeply integrating technological empowerment with product pipeline advantages, thereby achieving a full-chain upgrade from drug supply to health services.

According to reports, Fangzhou Pharmaceutical possesses advantages in large-model technology, application scenario R&D capabilities, and end-to-end service capabilities in the field of “AI + Chronic Disease Management,” while Vigonvita has accumulated profound expertise in R&D and product pipelines within the biopharmaceutical sector. Taking this strategic signing as a new starting point, both parties will leverage their respective core strengths to engage in deep collaboration, jointly building a “customer-centric” health service system. They are committed to providing comprehensive, full-lifecycle health management solutions that are precisely tailored, efficient, convenient, professional, and standardized for a broad user base.

At the Partner Summit, Fangzhou Pharmaceutical and Vigonvita Signed a Strategic Cooperation Agreement

Dr. Tian Guanghui, Chairman and General Manager of VigonvitaExpressing strong optimism about the prospects of this collaboration, he stated, “Fangzhou Pharmaceutical’s achievements in ‘AI + Chronic Disease Management’ and digital-intelligent marketing are widely recognized. Its spirit of exploration in addressing industry pain points through technological innovation aligns closely with Vigonvita’s operational philosophy. Through this strategic partnership, we aim to bridge the critical gap between biopharmaceutical R&D and health services, ensuring that R&D outcomes more precisely meet user needs. By leveraging digital tools, we strive to deliver high-quality pharmaceutical products and professional health services more efficiently to households across the nation.”

Against the backdrop of an increasingly clear national development path for “AI+,” the convening of this Partner Summit not only demonstrated Fangzhou Pharmaceutical’s forward-looking layout and technical strength in the field of “AI + Chronic Disease Management,” but also established a new ecosystem of industrial synergy through strategic signings. Looking ahead, Fangzhou Pharmaceutical will continue to deepen its engagement in chronic disease management, constantly solidify its technological foundation, and strengthen the research and development of application scenarios. By leveraging technological power to drive the digital and intelligent upgrade of health services, the company aims to join hands with more partners to build a future for the big health industry that is inclusive, efficient, and intelligent.